VIA Pharmaceuticals (VIAP) 8-K Regulation FD Disclosure

1

VIA Pharmaceuticals

VIA Pharmaceuticals

Presentation

Presentation

August 2007

Exhibit 99.1

2

SAFE HARBOR

SAFE HARBOR

This

presentation

contains

“forward-looking”

statements

within

the

meaning

of

the

Private

Securities

Litigation

Reform

Act

of

1995. 

These

statements

relate

to

future

events

or

to

our

future

financial

performance

and

involve

known

and

unknown

risks,

uncertainties

and

other

factors

that

may

cause

our

actual

results,

levels

of

activity,

performance

or

achievements

to

be

materially

different

from

any

future

results,

levels

of

activity,

performance

or

achievements

expressed

or

implied

by

these

forward-looking

statements.

In

some

cases,

you

can

identify

forward-looking

statements

by

the

use

of

words

such

as

“may,”

“could,”

“expect,”

“intend,”

“plan,”

“seek,”

“anticipate,”

“believe,”

“estimate,”

“predict,”

“potential,”

“continue”

or

the

negative

of

these

terms

or

other

comparable

terminology.

You

should

not

place

undue

reliance

on

forward-looking

statements

since

they

involve

known

and

unknown

risks,

uncertainties

and

other

factors

which

are,

in

some

cases,

beyond

our

control

and

which

could

materially

affect

actual

results,

levels

of

activity,

performance

or

achievements.

Factors

that

may

cause

actual

results

to

differ

materially

from

current

expectations

include,

but

are

not

limited

to:

(i)

our

ability

to

comply

with

the

registration

requirements

set

forth

in

the

securities

purchase

agreement

with

respect

to

the

private

placement

and

to

timely

file

and

have

declared

effective

a

resale

registration

statement

registering

the

common

stock

sold

pursuant

to

the

securities

purchase

agreement

to

avoid

payment

of

liquidated

damages;

(ii)

our

ability

to

obtain

necessary

financing;

(iii)

our

ability

to

control

our

operating

expenses;

(iv)

our

ability

to

recruit

and

enroll

patients

for

the

CEA

and

ACS

clinical

trials;

(v)

our

ability

to

successfully

complete

our

clinical

trials

of

VIA-2291

on

expected

timetables

and

the

outcomes

of

such

clinical

trials;

(vi)

our

ability

to

obtain

necessary

FDA

approvals,

our

ability

to

successfully

commercialize

VIA-2291;

(vii)

our

ability

to

obtain

and

protect

our

intellectual

property

related

to

our

product

candidates;

(viii)

our

potential

for

future

growth

and

the

development

of

our

product

pipeline;

(ix)

our

ability

to

form

and

maintain

collaborative

relationships

to

develop

and

commercialize

our

product

candidates;

(x)

general

economic

and

business

conditions;

and

the

other

risks

described

under

“Risk

Factors”

in

VIA

Pharmaceuticals,

Inc.’s

Form

10-Q

for

the

quarter

ended

June

30,

2007,

which

was

filed

with

the

SEC

on

August

14,

2007.

All

forward-looking

statements

attributable

to

us

or

persons

acting

on

our

behalf

are

expressly

qualified

in

their

entirety

by

the

cautionary

statements

set

forth

above.

Forward-looking

statements

speak

only

as

of

the

date

they

are

made,

and

we

undertake

no

obligation

to

update

publicly

any

of

these

statements

in

light

of

new

information

or

future

events.

This

presentation

does

not

constitute

an

offer

to

sell

or

a

solicitation

of

an

offer

to

purchase

any

securities

of

any

nature

whatsoever,

nor

do

the

contents

of

the

presentation

constitute

legal,

tax

or

business

advice.

3

VIA Investment Highlights

VIA Investment Highlights

Late stage Phase II company with focus on inflammation

in atherosclerosis

•

Phase II DSMB Safety / Efficacy –

Q4 2007

•

Phase II data expected –

1

st

half 2008

Proprietary technology platform licensed from Stanford

creating strong product pipeline

Products target large cardiovascular markets in

combination with other existing treatments

Experienced management drives current momentum

4

Focus on Vascular Inflammation

Focus on Vascular Inflammation

in Atherosclerosis

in Atherosclerosis

5

Inflammation is Key in Atherosclerosis

Inflammation is Key in Atherosclerosis

VIA proprietary data suggests that

reduction in inflammation will reduce

Major Adverse Cardiac Events (MACE)

Convergent data underscores the

role inflammation plays in MACE

Site

of

intimal

rupture

or

erosion

of

thrombosed

coronary

atherosclerotic

plaques

is

characterized

by

an

inflammatory

process

irrespective

of

the dominant plaque morphology.

van der

Wal

AC, Becker AE, van der

Loos

CM, Das PK.

Circulation.1994 Jan;89(1):36-44

6

Atherosclerosis is VIA’s

Atherosclerosis is VIA’s

Area of Focus

Area of Focus

Inflammation is a key to all stages of the disease

Plaque rupture is a cause of MACE

MACE

Healthy artery

Early stages of

atherosclerosis

Inflammatory

process

Early atherosclerotic

lesions

Vulnerable

plaque

Stable plaque

CHD RISK

STARTS HERE

CHD

STARTS HERE

Leukotrienes

Mediate Vascular Inflammation

5-LO is the rate limiting enzyme

•

Inhibition is therapeutic in asthma

VIA identified 5-LO as target for

atherosclerosis

•

Human genetic data implicates 5-LO in MACE

•

Expression data in mouse and man shows

increased expression in disease

•

Inhibition of 5-LO reduces plaque inflammation in

atherosclerosis model

Published data converge on 5-LO for

atherosclerosis

•

Mouse and human genetics

•

Mechanistic studies in animal models

•

5-LO levels in clinically active and unstable plaque

Arachidonic

Acid

LTA4

LTB4

LTC4

LTD4

LTE4

5-LO

FLAP

LTA4 H

LTA4 S

7

8

VIA is in Late Stage Clinical Trials

VIA is in Late Stage Clinical Trials

9

Late Stage Clinical Development Plan

Late Stage Clinical Development Plan

DSMB Review Safety / Efficacy

10

First VIA Drug is 5-LO Inhibitor

First VIA Drug is 5-LO Inhibitor

Strong product characteristics

•

ABT-761            Atreleuton

VIA-2291

•

Once daily oral dosing

•

Highly specific

•

Potential for greater therapeutic index

Extensive clinical experience –

more than 1,100 patients exposed

•

20 Phase I studies, 6 Phase II studies, 2 Phase III studies (pivotal)

•

Proven efficacy in asthma

•

Extensive safety data base

•

Development discontinued for commercial reasons

Broad license of worldwide rights

•

Exclusive worldwide license for any indication

•

VIA retains all commercial rights

NDA–ready CMC package

11

Significant Human Data on VIA-2291

Significant Human Data on VIA-2291

VIA-2291 Dose versus % LTB4 Inhibition

Human data from Abbott 1100 patients showing the effective inhibition of LTB4 at multiple doses

Time (hours)

0

5

10

15

20

25 mg

50 mg

75 mg

100 mg

12

Strong VIA Clinical Trial Design

Strong VIA Clinical Trial Design

Robust animal and human data for VIA-2291

Integration of histology, imaging and biomarker endpoints

Demonstrate direct impact on disease process

State of the art design -

FDA “Critical Path”

initiative

13

Ongoing VIA-2291 Clinical Trials -

Ongoing VIA-2291 Clinical Trials -

CEA

CEA

Trial

Phase II CEA

Population

Carotid artery disease

Carotid Endarterectomy

Description

40 patients scheduled for CEA

Randomized, double-blind

3 months 100mg/day or placebo pre-surgery

Endpoints

Inhibition of 5-LO 

Inflammatory biomarkers 

Plaque inflammation and histology

Result

Confirm mechanism of action

Demonstrate impact on plaque 

Confirm safety

Investigator

Francesco Cipollone, MD

Clinical sites in Italy

14

Ongoing VIA-2291 Clinical Trials -

Ongoing VIA-2291 Clinical Trials -

ACS

ACS

Trial

Phase II ACS

Population

Coronary artery disease

Acute Coronary Syndrome

Description

200 patients within 21 days of heart

attack

Randomized, double-blind

3 months 25mg/day, 50 mg/day, 100

mg/day or placebo

Endpoints

Inhibition of 5-LO 

Inflammatory biomarkers

Coronary lesions on MDCT scan

Result

Select dose

Demonstrate anti inflammatory effect

Confirm safety

Investigator

Jean-Claude Tardif, MD

Clinical sites in US and Canada

15

Strong VIA-2291 Patent Coverage

Strong VIA-2291 Patent Coverage

Issued US Patent

•

Composition of Matter

•

Discloses and claims VIA-2291 as a species and genus and claims pharmaceutical

compositions containing VIA-2291

•

Expires: November 6, 2012 (US); November 6, 2013 (major EU markets)

Patent Extension & Regulatory Strategies

•

Potentially eligible for up to 5 years patent extension under Hatch-Waxman

•

5 year data exclusivity for new molecular entity; 10 year in EU and Japan

New Patent Application

•

Methods of use -

20 years patent

•

Discloses and claims methods of using VIA-2291 and its derivatives for the

treatment of cardiovascular diseases caused by atherosclerosis

•

Filed August 7, 2006

Potential Strategies

•

Combinations

•

Advanced formulations

16

Vascular Inflammation Targets

Vascular Inflammation Targets

Large Markets

Large Markets

17

Significant Drug Costs

Significant Drug Costs

Cholesterol

Hypertension

Anti-Thrombotics

Other

15.8 million cases in US and

1.4 million at “high risk”

Current therapies treat only

risk factors

AHA estimates 700,000 first

time and 500,000 recurrent

heart attacks in 2007

$26.2 B

$27.2

B

$10.5 B

$5.2 B

WW Cardiovascular Market

>$69 billion in 2005

Source:Defined

Health 2006

18

Large Unmet Medical Need

Large Unmet Medical Need

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

IDEAL

Prove IT

HPS

4S

LIPID

CARE

CAPRIE

Risk not addressed

Reduction in MACE

Lipitor

Zocor

Pravachol

Published Results

Plavix

19

Strong Focus on Product Pipeline

Strong Focus on Product Pipeline

20

Broad Development Pipeline

Broad Development Pipeline

Compound/Target

Applications

Research

Pre-Clinical

Phase I

Phase II

Phase III

NDA

VIA-2291 / 5-LO

Acute Coronary Syndrome

CEA

PDE 4

Vascular Inflammation

LTA4 Hydrolase

Vascular Inflammation

Novel Targets

Vascular Inflammation

21

VIA Proprietary Technology Platform

VIA Proprietary Technology Platform

4 year, $30 million study at Stanford headed by VIA Founder/CSO

•

Inflammation key in human atherosclerosis

•

Extensive data from work in mouse model confirms human findings

•

>3,000 patient study confirms inflammatory genes in heart attack

and stroke

Database for prioritizing target classes and compounds

Model and assays to evaluate compounds

Significant leverage in targeting / developing compounds

Exclusively licensed to VIA

22

Broad Pool of Anti Inflammatory Compounds

Broad Pool of Anti Inflammatory Compounds

Qualified Targets

Anti inflammatory

Compounds

Identified

Opportunities

Preclinical

Clinical

Stage

LOs

(5-LO, 12-LO, FLAP)

189

109

75

34

Leukotrienes

(LTA4, LTB4, LTC4, LTD4)

189

189

135

54

PPARs

99

92

52

40

PDEs

(mostly PDE4)

153

153

95

58

Chemokines, cytokines

133

133

96

36

Phospholipase

A2 (PLA2)

48

41

38

3

PAF

134

134

105

29

Kinases

(p38, rho)

22

12

8

4

Cell adhesion (VLA4, VCAM)

89

27

18

9

Other classes

3,754

467

373

171

TOTAL

4,810

1358

995

438

23

Data Shows 35% Reduction in Inflammation

Data Shows 35% Reduction in Inflammation

*

*

Reduction in mouse model plaque macrophage with VIA-2291

*

p < 0.05

24

Significant Progress

Significant Progress

Company:

VIA Pharmaceuticals, Inc.

Ticker:

NASDAQ -

VIAP

Amount:

$25 Million

Security:

Unregistered Common Stock –

PIPE

Use of Proceeds:  

Working Capital and

General Corporate Purposes

Closing:   

July 2, 2007 1

st

Close

August 8, 2007 2

nd

Close

Completed Stock Offering

25

26

Milestones and Drivers of Value

Milestones and Drivers of Value

2005

2006

2007

Q1:  License

from

Stanford

Q3: Licensed

VIA-2291

Q1:  IND Filed

for VIA-2291

Q3:  Initiate Ph

II for VIA-2291

Late 2007: VIA-2291 Ph II

DSMB Safety / Efficacy

Early 2008:  Ph II

Results for VIA-2291

2008

Development

and

Operations

Series A Financing

Corautus Merger

Financing

Milestones

VIA Public Company

2008: Anticipated IND for

2nd  Product

PDE4 & LTA4

programs

27

Financial Update

Financial Update

Cash balance

•

Approximately $8 million at close of merger (net of costs)

•

Approximately $31 million after PIPE closing

Cash burn –

approx $1.6 -

$1.7million / month at present

Total common shares outstanding 19.7 million

Fully diluted shares outstanding 21.0 million

28

VIA Value Proposition

VIA Value Proposition

Low risk drug development platform

Strong and building pipeline

Scalable business model with significant leverage

Strong value proposition for potential partners

Attractive valuation

Position

Personnel

Experience

CEO

Larry Cohen, PhD

Zymoyx, Progenitor, Somatix, Therion

CMO

Oye Olukotun, MD, MPH

Bristol Myers Squibb, Mallinckrodt, Esperion

CSO

Tom Quertermous, MD

Dept Cardiovascular Medicine, Stanford Medical School

CDO

Mike Perry, DVM, PhD

Baxter, Novartis, Schering-Plough

SVP CFO

Jim Stewart

ACT, CN Biosciences, Ventro, E&Y

VP Clinical

Melisa Cooper, MD, MS

Bristol Myers Squibb

VP Bus Dev

Brendan Rae, PhD, JD

Roche, Purdue Pharma

29

Experienced Management Team

Experienced Management Team

30

World Class Advisors

World Class Advisors

Scientific Advisors

Israel Charo, MD, PhD

Assoc. Dir, Gladstone Institute of Cardiovascular Disease, UCSF

Christopher Glass, MD, PhD

Professor, Cellular and Molecular Medicine, UCSD

Colin Funk, PhD

Professor, Biochemistry and Physiology, Queens University

Garret FitzGerald, MD

Chairman Pharmacology, University of Pennsylvania

Marco Conti, MD

Professor Ob Gyn, Stanford Medical School

Tod

Klingler, PhD

VP Information Sciences, XDx, Inc

Drug  Assessment Advisors

Len Post, PhD

Former VP Discovery, Parke-Davis

Peter Myers, PhD

Former VP of Chemistry Research, Glaxo

Felix de la Iglesia, MD

Former VP, WW Pre-Clinical Safety, Warner-Lambert

Saul Cherkofsky, PhD

Former

Executive

Director

Pharmaceuticals,

Dupont

Merck

Alex Giaquinto, PhD

Former SVP WW Regulatory Affairs, Schering Plough

Clinical Advisors & Investigators

Marc Pfeffer, MD, PhD

Professor, Department of Medicine, Harvard Medical School

Jean-Claude Tardif, MD

Director, Research Center, Montreal Heart Institute

Francesco Cipollone, MD

Professor, “G. d’Annunzio”

University, School of Medicine

31

VIA Investment Highlights

VIA Investment Highlights

Late stage Phase II company with focus on inflammation

in atherosclerosis

•

Phase II DSMB Safety / Efficacy –

Q4 2007

•

Phase II data expected –

1

st

half 2008

Proprietary technology platform licensed from Stanford

creating strong product pipeline

Products target large cardiovascular markets in

combination with other existing treatments

Experienced management drives current momentum